We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
MorphoSys Announces Extension of Antibody Alliance with Schering-Plough
News

MorphoSys Announces Extension of Antibody Alliance with Schering-Plough

MorphoSys Announces Extension of Antibody Alliance with Schering-Plough
News

MorphoSys Announces Extension of Antibody Alliance with Schering-Plough

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "MorphoSys Announces Extension of Antibody Alliance with Schering-Plough"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

MorphoSys AG has announced that Schering-Plough Corporation has triggered its pre-existing option to extend the current collaboration between the two companies for another year. The partnership, which was initiated in May 2006, may be extended by Schering-Plough annually until 2011.

The agreement grants Schering-Plough continued access to MorphoSys's proprietary antibody library HuCAL GOLD at its research site, Schering-Plough Biopharma, in Palo Alto, Calif., and contains options for therapeutic licenses.

For therapeutic antibody projects undertaken by Schering-Plough, MorphoSys is eligible to receive license fees, plus milestone payments relating to the successful advancement of projects in clinical development, and royalties on HuCAL antibodies developed under the agreement. Under the extended agreement, MorphoSys continues to receive annual user fees for access to its HuCAL platform. Further financial details were not disclosed.

"We are pleased with Schering-Plough's decision to extend the current collaboration," comments Dr. Simon Moroney, Chief Executive Officer of MorphoSys. "Today's news demonstrates once more the continued commitment of leading pharmaceutical companies worldwide to our HuCAL technology for their antibody-based drug development programs."
Advertisement